GH Research PLC (GHRS) director details share and option holdings
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
GH Research PLC director Dermot John Hanley filed an initial ownership report listing his existing equity position in the company. The filing shows direct ownership of 2,432 Ordinary Shares as of March 18, 2026.
Hanley also holds several tranches of Share Options (Right to Buy) over Ordinary Shares with an exercise price of 0.0250 per share and expirations ranging from September 26, 2030 to September 3, 2032. These options cover 6,633, 5,508, 5,532, 50,000 and 4,667 underlying Ordinary Shares, respectively. Footnotes indicate the options are fully vested or vesting over time and may be exercised within specified multi‑year windows under the GH Research PLC Share Option Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Hanley Dermot John
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Options (Right to Buy) | -- | -- | -- |
| holding | Share Options (Right to Buy) | -- | -- | -- |
| holding | Share Options (Right to Buy) | -- | -- | -- |
| holding | Share Options (Right to Buy) | -- | -- | -- |
| holding | Share Options (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Options (Right to Buy) — 6,633 shares (Direct);
Ordinary Shares — 2,432 shares (Direct)
Footnotes (1)
- The share options are fully vested and exercisable. The share options are fully vested and, subject to the rules of the GH Research PLC Share Option Plan, may be exercised between the second and seventh anniversary of June 22, 2024. The share options are fully vested and, subject to the rules of the GH Research PLC Share Option Plan, may be exercised between the second and seventh anniversary of July 6, 2024. The share options vested as to 25% on December 9, 2025, and the remaining share options vest in equal monthly installments for three years thereafter. The share options are fully vested and, subject to the rules of the GH Research PLC Share Option Plan, may be exercised between the second and seventh anniversary of September 3, 2025.
Key Figures
Ordinary Shares held: 2,432 shares
Option exercise price: 0.0250 per share
Options expiring 2030-09-26: 6,633 underlying shares
+4 more
7 metrics
Ordinary Shares held
2,432 shares
Direct ownership as of March 18, 2026
Option exercise price
0.0250 per share
Share Options (Right to Buy) over Ordinary Shares
Options expiring 2030-09-26
6,633 underlying shares
Share Options (Right to Buy), direct ownership
Options expiring 2031-06-22
5,508 underlying shares
Share Options (Right to Buy), direct ownership
Options expiring 2031-07-06
5,532 underlying shares
Share Options (Right to Buy), direct ownership
Options expiring 2031-12-09
50,000 underlying shares
Share Options (Right to Buy), vesting over time
Options expiring 2032-09-03
4,667 underlying shares
Share Options (Right to Buy), fully vested per plan rules
Key Terms
Share Options (Right to Buy), Ordinary Shares, exercise price, fully vested, +1 more
5 terms
exercise price financial
"conversion_or_exercise_price: "0.0250""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
fully vested financial
"The share options are fully vested and exercisable."
FAQ
What does Dermot John Hanley report owning in GHRS on this Form 3?
Dermot John Hanley reports direct ownership of 2,432 Ordinary Shares of GH Research PLC, plus multiple tranches of share options over additional Ordinary Shares, all summarized as of March 18, 2026 in this initial ownership statement.
What is the significance of this GHRS Form 3 filing by Dermot John Hanley?
This Form 3 serves as an initial statement of beneficial ownership for director Dermot John Hanley. It outlines his existing Ordinary Share holdings and detailed option grants but does not itself describe new open-market purchases or sales of GH Research PLC stock.